Treating An Elderly Woman with Chronic Lymphocytic Leukemia
Treating An Elderly Woman with Chronic Lymphocytic Leukemia
An Elderly Woman With CLL
- A 78-yearold female presented with symptoms of fatigue and loss of appetite for the past six months
- PMH: recurrent bronchitis during past 12 months, treated with antibiotics
- PE: vital signs WNL, right cervical lymphadenopathy, spleen palpable 5 cm below costal margin, otherwise well-appearing
- Laboratory findings:
- WBC, 53,000; 76% lymphocytes
- Hb; 10.4 g/dL
- Platelets; 150 X 109/L
- ANC; 180/mm3
- Flow cytometry; CD5+, CD19+, CD23+
- Cytogenetics, FISH: trisomy 12; IgVH mutated
- β2M, 3.6 mg/L
- BM biopsy; diffuse infiltration by CLL
- Diagnosis; chronic lymphocytic leukemia
- The patient was treated with ibrutinib and achieved a complete response to therapy after 4 months
Marks Explores Cardiac Toxicities and Dosing Concerns of BTK Inhibitors in CLL
April 26th 2024During a Case-Based Roundtable® event, Stanley M. Marks, MD, moderated a discussion on the impact of cardiac adverse events on patients who receive a Bruton tyrosine kinase inhibitor for chronic lymphocytic leukemia.
Read More
Considering the Durability of Zanubrutinib in Relapsed/Refractory CLL
April 11th 2024During a Case-Based Roundtable® event, Marc S. Hoffmann, MD, discussed his viewpoints on the use of Bruton tyrosine kinase inhibitors for patients with relapsed/refractory chronic lymphocytic leukemia and the efficacy behind zanubrutinib in the second article of a 2-part series.
Read More
Acalabrutinib/Obinutuzumab Shows Improved PFS in Treatment-Naive CLL
April 10th 2024In an interview with Targeted Oncology, Jeff Sharman, MD, discussed the results of the ELEVATE-TN trial of acalabrutinib with or without obinutuzumab at 74.5 months of follow-up among patients with chronic lymphocytic leukemia.
Read More
